Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAX Baxter International	$17.41 +2.5%	$17.74	$15.73 ▼ $32.68	$8.98B	0.62	9.39 million shs	3.59 million shs
DXCM DexCom	$61.00 +1.1%	$65.34	$54.11 ▼ $89.98	$23.52B	1.4	4.93 million shs	2.40 million shs
FSNUY Fresenius SE & Co.	$12.05 +1.2%	$13.13	$11.28 ▼ $33.93	$27.15B	0.68	92,917 shs	169,872 shs
RMD ResMed	$207.30 -1.1%	$231.31	$198.64 ▼ $293.81	$30.21B	0.84	1.14 million shs	636,662 shs
TFX Teleflex	$133.24 +8.1%	$119.05	$100.18 ▼ $139.67	$5.87B	0.82	963,741 shs	775,668 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAX Baxter International	+1.40%	+0.51%	+1.96%	-21.94%	-43.32%
DXCM DexCom	+1.48%	+4.86%	-4.51%	-13.64%	-26.04%
FSNUY Fresenius SE & Co.	+2.58%	-1.81%	-5.78%	-18.14%	-1.81%
RMD ResMed	+0.94%	-1.02%	-6.61%	-21.28%	-13.34%
TFX Teleflex	+2.17%	-7.39%	+7.03%	+16.64%	+2.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAX Baxter International	$17.41 +2.5%	$17.74	$15.73 ▼ $32.68	$8.98B	0.62	9.39 million shs	3.59 million shs
DXCM DexCom	$61.00 +1.1%	$65.34	$54.11 ▼ $89.98	$23.52B	1.4	4.93 million shs	2.40 million shs
FSNUY Fresenius SE & Co.	$12.05 +1.2%	$13.13	$11.28 ▼ $33.93	$27.15B	0.68	92,917 shs	169,872 shs
RMD ResMed	$207.30 -1.1%	$231.31	$198.64 ▼ $293.81	$30.21B	0.84	1.14 million shs	636,662 shs
TFX Teleflex	$133.24 +8.1%	$119.05	$100.18 ▼ $139.67	$5.87B	0.82	963,741 shs	775,668 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAX Baxter International	+1.40%	+0.51%	+1.96%	-21.94%	-43.32%
DXCM DexCom	+1.48%	+4.86%	-4.51%	-13.64%	-26.04%
FSNUY Fresenius SE & Co.	+2.58%	-1.81%	-5.78%	-18.14%	-1.81%
RMD ResMed	+0.94%	-1.02%	-6.61%	-21.28%	-13.34%
TFX Teleflex	+2.17%	-7.39%	+7.03%	+16.64%	+2.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BAX Baxter International	1.92	Reduce	$19.91	14.39% Upside
DXCM DexCom	2.88	Moderate Buy	$83.50	36.89% Upside
FSNUY Fresenius SE & Co.	3.00	Buy	N/A	N/A
RMD ResMed	2.73	Moderate Buy	$286.18	38.05% Upside
TFX Teleflex	2.11	Hold	$133.57	0.25% Upside

Current Analyst Ratings Breakdown

Latest RMD, DXCM, FSNUY, BAX, and TFX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/4/2026	DXCM DexCom	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$84.00 ➝ $79.00
5/1/2026	DXCM DexCom	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$77.00
5/1/2026	RMD ResMed	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$225.00
5/1/2026	DXCM DexCom	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$80.00
5/1/2026	DXCM DexCom	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$75.00
5/1/2026	DXCM DexCom	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$81.00
5/1/2026	DXCM DexCom	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$95.00 ➝ $100.00
5/1/2026	DXCM DexCom	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Underweight	$72.00 ➝ $67.00
5/1/2026	BAX Baxter International	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target		$22.00 ➝ $20.00
5/1/2026	BAX Baxter International	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target		$20.00 ➝ $19.00
5/1/2026	BAX Baxter International	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$17.00 ➝ $19.00

(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BAX Baxter International	$11.32B	0.79	$5.90 per share	2.95	$11.65 per share	1.49
DXCM DexCom	$4.82B	4.89	$2.84 per share	21.48	$7.66 per share	7.96
FSNUY Fresenius SE & Co.	$25.87B	1.05	$1.62 per share	7.42	$9.93 per share	1.21
RMD ResMed	$5.54B	5.45	$11.17 per share	18.56	$44.56 per share	4.65
TFX Teleflex	$1.99B	2.96	$12.36 per share	10.78	$70.71 per share	1.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BAX Baxter International	-$957M	-$2.13	N/A	8.75	2.70	-9.70%	16.15%	5.24%	N/A
DXCM DexCom	$836.30M	$2.34	26.05	20.27	1.03	19.31%	33.33%	13.19%	N/A
FSNUY Fresenius SE & Co.	$1.43B	$0.63	19.13	10.57	N/A	5.71%	10.31%	4.78%	N/A
RMD ResMed	$1.40B	$10.37	20.00	17.12	1.32	27.44%	25.35%	18.69%	N/A
TFX Teleflex	-$905.64M	-$20.55	N/A	13.50	0.87	-30.56%	14.30%	7.45%	5/7/2026 (Estimated)

Latest RMD, DXCM, FSNUY, BAX, and TFX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	TFX Teleflex	$1.21	$1.39	+$0.18	-$0.18	$536.91 million	$548.30 million
5/6/2026	Q1 2026	FSNUY Fresenius SE & Co.	$0.2529	$0.24	-$0.0129	$0.23	$6.76 billion	N/A
4/30/2026	Q1 2026	BAX Baxter International	$0.31	$0.36	+$0.05	-$0.03	$2.62 billion	$2.70 billion
4/30/2026	Q1 2026	DXCM DexCom	$0.47	$0.56	+$0.09	$0.51	$1.17 billion	$1.19 billion
4/30/2026	Q3 2026	RMD ResMed	$2.79	$2.86	+$0.07	$2.74	$1.42 billion	$1.43 billion
2/26/2026	Q4 2025	TFX Teleflex	$3.73	$1.93	-$1.80	-$16.15	$912.57 million	$569.00 million
2/25/2026	Q4 2025	FSNUY Fresenius SE & Co.	N/A	$0.28	N/A	$0.18	N/A	$6.94 billion
2/12/2026	Q4 2025	BAX Baxter International	$0.53	$0.44	-$0.09	-$2.19	$2.82 billion	$2.97 billion
2/12/2026	Q4 2025	DXCM DexCom	$0.65	$0.68	+$0.03	$0.68	$1.25 billion	$1.26 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BAX Baxter International	$0.04	0.23%	-11.54%	N/A	N/A
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
FSNUY Fresenius SE & Co.	$0.19	1.58%	N/A	30.16%	N/A
RMD ResMed	$2.40	1.16%	+6.33%	23.14%	13 Years
TFX Teleflex	$1.36	1.02%	N/A	N/A	N/A

Latest RMD, DXCM, FSNUY, BAX, and TFX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2026	BAX Baxter International	quarterly	$0.01	0.23%	5/29/2026	5/29/2026	7/1/2026
4/30/2026	RMD ResMed	quarterly	$0.60	1.12%	5/14/2026	5/14/2026	6/18/2026
2/11/2026	BAX Baxter International	quarterly	$0.01	0.2%	2/27/2026	2/27/2026	4/1/2026
2/24/2026	TFX Teleflex	quarterly	$0.34	1.2%	3/6/2026	3/6/2026	3/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BAX Baxter International	1.43	1.85	1.23
DXCM DexCom	0.42	1.95	1.64
FSNUY Fresenius SE & Co.	0.47	1.32	1.00
RMD ResMed	0.06	3.01	2.33
TFX Teleflex	0.81	2.54	2.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BAX Baxter International	90.19%
DXCM DexCom	97.75%
FSNUY Fresenius SE & Co.	N/A
RMD ResMed	54.98%
TFX Teleflex	95.62%

Insider Ownership

Company	Insider Ownership
BAX Baxter International	0.17%
DXCM DexCom	0.28%
FSNUY Fresenius SE & Co.	N/A
RMD ResMed	0.65%
TFX Teleflex	0.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BAX Baxter International	37,500	516.47 million	515.59 million	Optionable
DXCM DexCom	11,000	385.87 million	384.79 million	Optionable
FSNUY Fresenius SE & Co.	178,394	2.25 billion	N/A	Not Optionable
RMD ResMed	10,600	145.68 million	144.73 million	Optionable
TFX Teleflex	15,500	44.26 million	43.96 million	Optionable

RMD, DXCM, FSNUY, BAX, and TFX Headlines

Recent News About These Companies

Teleflex Incorporated 2026 Q1 - Results - Earnings Call Presentation

3 hours ago | seekingalpha.com

Compared to Estimates, Teleflex (TFX) Q1 Earnings: A Look at Key Metrics

4 hours ago | zacks.com

Teleflex (TFX) Tops Q1 Earnings and Revenue Estimates

May 7 at 9:56 AM | zacks.com

Teleflex Posts Q1 Results, Maintains 2026 Outlook, Plans Buyback

May 7 at 8:11 AM | tipranks.com

Teleflex (NYSE:TFX) Issues FY 2026 Earnings Guidance

May 7 at 7:43 AM | marketbeat.com

Teleflex Reports First Quarter Financial Results and Full Year 2026 Outlook

May 7 at 7:03 AM | businesswire.com

Teleflex earnings: What to look for from TFX

May 6 at 9:36 AM | msn.com

Strs Ohio Acquires 11,002 Shares of Teleflex Incorporated $TFX

May 6 at 5:44 AM | marketbeat.com

Teleflex (TFX) Projected to Post Earnings on Thursday

May 6 at 4:17 AM | americanbankingnews.com

Teleflex Incorporated $TFX Shares Sold by Vanguard Group Inc.

May 5 at 8:19 AM | marketbeat.com

PFA Pension Forsikringsaktieselskab Buys New Position in Teleflex Incorporated $TFX

May 5 at 5:53 AM | marketbeat.com

Head-To-Head Review: Teleflex (NYSE:TFX) and LivaNova (NASDAQ:LIVN)

May 5 at 4:49 AM | americanbankingnews.com

Teleflex Inc. stock underperforms Friday when compared to competitors

May 2, 2026 | marketwatch.com

Teleflex Names Jason Weidman CEO As Valuation Gap And Risks Draw Focus

May 1, 2026 | finance.yahoo.com

Teleflex Names Jason Weidman as New CEO

April 30, 2026 | tipranks.com

Teleflex (NYSE:TFX) Trading Down 7% - What's Next?

April 30, 2026 | marketbeat.com

Teleflex picks Medtronic Coronary, Renal Denervation leader Weidman as new CEO

April 30, 2026 | massdevice.com

Teleflex (TFX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

April 30, 2026 | zacks.com

Zacks Research Upgrades Teleflex (NYSE:TFX) to "Hold"

April 30, 2026 | marketbeat.com

Teleflex Appoints Jason Weidman as President and CEO

April 30, 2026 | businesswire.com

Teleflex Incorporated $TFX Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH

April 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RMD, DXCM, FSNUY, BAX, and TFX Company Descriptions

Baxter International NYSE:BAX

$17.40 +0.43 (+2.50%)

As of 02:58 PM Eastern

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

DexCom NASDAQ:DXCM

$61.00 +0.64 (+1.06%)

As of 02:57 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Fresenius SE & Co. OTCMKTS:FSNUY

$12.05 +0.14 (+1.18%)

As of 02:41 PM Eastern

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

ResMed NYSE:RMD

$207.30 -2.34 (-1.11%)

As of 02:58 PM Eastern

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Teleflex NYSE:TFX

$133.24 +10.01 (+8.12%)

As of 02:58 PM Eastern

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RMD, DXCM, FSNUY, BAX, and TFX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RMD, DXCM, FSNUY, BAX, and TFX Earnings

Compare Dividends

Latest RMD, DXCM, FSNUY, BAX, and TFX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RMD, DXCM, FSNUY, BAX, and TFX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RMD, DXCM, FSNUY, BAX, and TFX Company Descriptions

Baxter International NYSE:BAX

DexCom NASDAQ:DXCM

Fresenius SE & Co. OTCMKTS:FSNUY

ResMed NYSE:RMD

Teleflex NYSE:TFX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools